• Abbisko received FDA IND clearance for ABSK211, an oral pan-KRAS inhibitor, in advanced solid tumors with KRAS alterations.
• The US study will start as an open-label Phase 1 trial to evaluate safety, tolerability, efficacy, pharmacokinetics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260713-12241984), on July 13, 2026, and is solely responsible for the information contained therein.